

## UNBUNDLING GENE PRODUCTS FOR RARE DISEASES FROM CURRENT REIMBURSEMENTS TO HOSPITALS ([SF4058/HF3664](#))

New policies that support the rare disease community in Minnesota: *What you should know*

The Minnesota Legislature enacted legislation to enhance the reimbursement process for bio-logical products used in cell or gene therapy to treat rare diseases. These bills authorize the Commissioner of Human Services to provide separate reimbursement for these biological products when administered in an inpatient hospital setting.



### WHAT IT DOES

This update provides separate reimbursement for biological products provided in the inpatient hospital setting as part of cell or gene therapy to treat rare diseases separate from the associated diagnostic-related group (DRG).

### HOW IT HELPS THE COMMUNITY

This allows an increase in access to emerging and innovative treatments, hospitals to provide gene therapy without significant financial loss, and payers to enter into value-based arrangements with manufacturers.

### HOW IT WORKS

With the passing of this update, gene therapy products administered in an inpatient setting will now be unbundled from the DRG.

### WHEN DOES THE POLICY GO INTO EFFECT?

This policy goes into effect January 1st, 2025.

**LEARN MORE** For more information on RDAC policy goals, click [here](#).